NCT04920331View on ClinicalTrials.gov

Study of Intravenous Erenumab in Patients With Status Migrainosus

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 7, 2021

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions

Status Migrainosus

Interventions

BIOLOGICAL

Erenumab

140mg single intravenous administration (60 minutes)

Trial Locations (1)

85054

Mayo Clinic in Arizona, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT04920331 - Study of Intravenous Erenumab in Patients With Status Migrainosus | Biotech Hunter | Biotech Hunter